Name: PF-04620110
Brand: Selleck Chemicals
SKU: S7192
Availability: InStock
Rating: 5 (4 reviews)

Jump to

Quality Control

Batch: S719201 DMSO]49 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false Purity: 99.22%

Cited in Nature Medicine for its top-tier quality
COA
NMR
HPLC
SDS
Datasheet

99.22

Related Targets	Dehydrogenase HSP P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism Drug Metabolite
Other Transferase Inhibitors	Tunicamycin Ezatiostat FK866 (Daporinad) GGTI 298 TFA salt AOA (Aminooxyacetic acid) hemihydrochloride OSMI-4 A-922500 (DGAT-1 Inhibitor 4a) FIDAS-3 SGN-2FF ERG240

Solubility

In vitro
Batch:

DMSO : 49 mg/mL (123.6 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.400mg/ml (1.01mM)	Taking the 1 mL working solution as an example, add 50 μL of 8 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.400mg/ml (1.01mM)	Taking the 1 mL working solution as an example, add 50 μL of 8 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	396.44	Formula	C₂₁H₂₄N₄O₄	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	1109276-89-2	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			Smiles	C1CC(CCC1CC(=O)O)C2=CC=C(C=C2)N3CCOC4=NC=NC(=C4C3=O)N

Mechanism of Action

Targets/IC₅₀/Ki	DGAT1 19 nM
In vivo	In Rats, PF-04620110 reduces plasma triglyceride levels t doses of ≥0.1 mg/kg following a lipid challenge. DGAT1 inhibition by this compound causes an enrichment of polyunsaturated fatty acids within the TG class of lipids in rodents.
References	[1] https://pubmed.ncbi.nlm.nih.gov/24900321/ [2] https://pubmed.ncbi.nlm.nih.gov/23558010/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01298518	Completed	Type 2 Diabetes Patients	Pfizer	February 2011	Phase 1
NCT01166217	Completed	Healthy	Pfizer\|Bristol-Myers Squibb	July 2010	Phase 1
NCT01146327	Completed	Healthy	Pfizer\|Bristol-Myers Squibb	June 2010	Phase 1
NCT01064492	Completed	Healthy Volunteers	Pfizer	February 2010	Phase 1
NCT00959426	Completed	Obesity\|Overweight\|Healthy	Pfizer\|Bristol-Myers Squibb	August 2009	Phase 1
NCT00799006	Completed	Overweight	Pfizer	November 2008	Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

PF-04620110 Transferase inhibitor

Chemical Structure

Molecular Weight: 396.44